{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/management/biologics/","result":{"pageContext":{"chapter":{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics","depth":2,"htmlHeader":"<!-- begin field 68a77f41-ab75-4b7b-b3e8-aa41acfd9fc0 --><h2>Scenario: Biologics</h2><!-- end field 68a77f41-ab75-4b7b-b3e8-aa41acfd9fc0 -->","summary":"Covers the monitoring of biologics in adults in primary care.","htmlStringContent":"<!-- begin item eb34468a-65c5-4757-8a4c-c1d90bbd5fc9 --><!-- begin field 06a4472d-1daf-429a-be78-acbc015c27a6 --><p>From age 18 years onwards.</p><!-- end field 06a4472d-1daf-429a-be78-acbc015c27a6 --><!-- end item eb34468a-65c5-4757-8a4c-c1d90bbd5fc9 -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"6c4d1822-7d34-5093-808c-3e1502a25e1a","slug":"biologics-monitoring-requirements","fullItemName":"Biologics monitoring requirements","depth":3,"htmlHeader":"<!-- begin field b790949f-a904-4ed4-b592-8a4f857e3fde --><h3>What monitoring is required for biologics?</h3><!-- end field b790949f-a904-4ed4-b592-8a4f857e3fde -->","summary":null,"htmlStringContent":"<!-- begin item b1e85774-1360-4591-8c88-b279fcc3ec63 --><!-- begin field 153ee8d3-8539-4639-82c6-abe360161731 --><ul><li>Prescribing of biologics will always be part of a shared-care protocol — treatment and initial monitoring of disease modifying anti-rheumatic drugs (DMARDs) is usually carried out by a specialist in secondary care.</li><li>Monitoring of biologics may be undertaken in secondary care, although for people also on non-biologic DMARDs (for example, methotrexate), monitoring of those may still occur in primary care. This will depend on local protocols.</li><li>In addition to the <a class=\"topic-reference internal-reference\" href=\"/topics/dmards/management/general-principles-of-managing-dmards/#general-principles-of-managing-dmards\">general principles of managing DMARDs</a>, Table 3 outlines the monitoring required for people on biologics. </li><li>Follow local guidelines where they differ from those in Table 3.<ul><li>Whilst absolute values are useful indicators, trends are equally important, and any rapid fall or consistent downward trend in any parameter warrants extra vigilance.</li></ul></li><li>People who are starting treatment with a biologic should be screened for active and latent tuberculosis (TB) before starting treatment. In addition, they should be monitored closely for infectious diseases (including TB) before, during, and after treatment — perhaps for as long as six months (depending on the half-life of the biologic).<ul><li>There is an increased risk of TB, or reactivation of latent TB, during treatment with biologics. Tuberculosis in people receiving biologics can be life-threatening, and deaths from TB have occurred. Biologics are therefore contraindicated in people with active TB or other severe infections.</li></ul></li><li>People should be assessed before each infusion (or self-assess before each injection) for signs of infection.</li><li>Other routine assessments include periodic skin examination for non-melanoma skin cancer for patients at increased risk (history of psoriasis or PUVA therapy).</li></ul><p><strong>Table 3.</strong> Primary care monitoring requirements for people taking biologics.</p><table><thead><tr><th colspan=\"1\">Monitoring</th><th colspan=\"1\">Frequency</th></tr></thead><tbody><tr><td colspan=\"1\">Full Blood Count (FBC)</td><td colspan=\"1\" rowspan=\"3\"><ul><li>At 3–4 months.</li><li>Then every 6 months (and/or as clinically indicated). </li></ul></td></tr><tr><td colspan=\"1\">Urea and electrolytes (U+E), including creatinine</td></tr><tr><td colspan=\"1\">Liver function tests (LFTs): ALT and/or AST and albumin.</td></tr><tr><td colspan=\"1\">Lipid profile<sup>*</sup> </td><td colspan=\"1\"><ul><li>Monitor 4–8 weeks after treatment started. <ul><li>Hyperlipidaemia should be managed according to clinical guidelines.</li></ul></li></ul></td></tr><tr><td colspan=\"1\">Hepatitis B</td><td colspan=\"1\" rowspan=\"6\"><ul><li>If clinically indicated.</li></ul></td></tr><tr><td colspan=\"1\">Hepatitis C</td></tr><tr><td colspan=\"1\">Urinalysis </td></tr><tr><td colspan=\"1\">Tuberculosis</td></tr><tr><td colspan=\"1\">HIV</td></tr><tr><td colspan=\"1\">Autoantibodies </td></tr><tr><td colspan=\"2\"><p>ALT, alanine aminotransferase; AST, aspartate aminotransferase. *Tocilizumab only.</p></td></tr><tr><td colspan=\"2\"><strong>Data from:</strong>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">RCN, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BAD, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017m</a>]</td></tr></tbody></table><!-- end field 153ee8d3-8539-4639-82c6-abe360161731 --><!-- end item b1e85774-1360-4591-8c88-b279fcc3ec63 -->","subChapters":[{"id":"d06c80ac-7015-51eb-b8a0-8e4b904083a2","slug":"basis-for-recommendation-b1f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e3a16172-64aa-448b-b9b9-5e1b4d910205 --><h4>Basis for recommendation</h4><!-- end field e3a16172-64aa-448b-b9b9-5e1b4d910205 -->","summary":null,"htmlStringContent":"<!-- begin item b1f203a7-10c5-42c9-9a49-e612b8b7ee8b --><!-- begin field b97f1744-1b8b-4c5e-aed9-c863e60baff5 --><p>These recommendations are based on the British Association of Dermatologists (BAD) <em>Guidelines for biologic therapy for psoriasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BAD, 2017</a>], the Royal College of Nursing (RCN) guideline <em>Assessing, managing and monitoring biologic therapies for inflammatory arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">RCN, 2015</a>], shared care guidelines for disease modifying antirheumatic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">NHS Worcestershire, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">NHS Barnsley Clinical Commissioning Group, 2015</a>], the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2013</a>], and the Summary of Product Characteristics for tocilizumab [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017m</a>].</p><h5>Primary care monitoring </h5><ul><li>The monitoring of biologic disease modifying antirheumatic drugs (DMARDs) may take place in primary care under a shared care arrangements. However, in some local DMARD protocols people on biologic monotherapy do not require monitoring in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">NHS Worcestershire, 2017</a>].<ul><li>Patients receiving biologic therapy require clinical review in secondary care at least every 6 months to allow on-going prescribing of their treatment. Monitoring blood tests will be undertaken at this appointment in secondary care where indicated.</li></ul></li><li>Under some shared care agreements, where people are prescribed a non-biologic DMARD and a biologic DMARD, monitoring of the biologic is done in secondary care while prescribing and monitoring of the non-biologic is still undertaken in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">NHS Barnsley Clinical Commissioning Group, 2015</a>].<ul><li>Subcutaneous biologics do not need any extra monitoring, as most biologics are given with methotrexate, 3 monthly blood testing is all that is necessary.</li><li>Where other monitoring is needed (for example, pre-infusion immunoglobulin levels in people receiving rituximab), this will be undertaken in secondary care.</li></ul></li></ul><h5>Frequency of monitoring</h5><ul><li>The BAD guideline recommends that monitoring of people on biologic DMARDs can be carried out every 6 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BAD, 2017</a>].</li><li>However, some guidelines suggest that monitoring is required every 3 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">RCN, 2015</a>].</li><li>CKS recommends following the recommendations of local guidelines.</li></ul><h5>Tuberculosis (TB) monitoring</h5><ul><li>Monitoring for TB should continued for 6 months after treatment with a biologic has stopped [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">RCN, 2015</a>].</li><li>Continue to monitor for TB infection six months after treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2013</a>].</li></ul><!-- end field b97f1744-1b8b-4c5e-aed9-c863e60baff5 --><!-- end item b1f203a7-10c5-42c9-9a49-e612b8b7ee8b -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}